Heme/Onc Fellow @NorthwesternMed |@umkcIM and @CCLRI research fellow alum | GI Onc/Pancreatic/Bile duct cancer | 🇹🇭/🏳️🌈 | Tweets=my own
Chicago, IL
Joined February 2020
- Tweets290
- Following755
- Followers341
- Likes1.1K
Ben Ponvilawan, MD, MS retweeted
Proud to share our latest publication in JCO Precision Oncology @JCOPO_ASCO @JCO_ASCO @RamSubraMD @BPonvilawan
In the largest study to date evaluating transcriptomic immune biomarkers in advanced NSCLC treated with immunotherapy, we found that:
• Immune-hot tumor microenvironments and high tertiary lymphoid structure (TLS) signatures were strongly associated with improved immunotherapy outcomes in lung adenocarcinoma
• These biomarkers outperformed traditional markers like PD-L1 in predicting benefit
• Dynamic immune trafficking and activation may be key drivers of response to checkpoint inhibitors
Excited about the potential for RNA-based immune profiling to refine precision immunotherapy in lung cancer.
#LungCancer #NSCLC #Immunotherapy #PrecisionOncology #ThoracicOncology #CancerResearch
ascopubs.org/doi/10.1200/PO-…
Ben Ponvilawan, MD, MS retweeted
🤩Honored to be a co-author on this important work led by our incredible attending Dr. Arya @royaryam, spotlighting the academic productivity of IMG fellows. Grateful for the opportunity to contribute!🙌
📅 Oral Presentation: 6/2/2025 | 9:45–9:51 AM
🔗 meetings.asco.org/abstracts-…
#ASCO2025 #IMG #MedTwitter #HemOnc #Oncology #Research
Excited to present our research on academic productivity of IMG fellows as an oral presentation at #ASCO25. Grateful for the opportunity to spotlight IMG contributions! @IMG_Oncologists @DrChoueiri @NazliDizman @ZiadBakouny @KarunNeupaneMD @ArdeshirFatemeh @OhioStateMedOnc
Ben Ponvilawan, MD, MS retweeted
🚨Save the date🚨
@ASCO #IMG Community of Practice Meeting at #ASCO25
⏰May 30st, 4-6 PM CST
📌Room S103, McCormick Place
Join us to discuss barriers & opportunities for IMGs
ASCO IMG CoP👉bit.ly/3JmJQwK
@ASCOPost #IMGoncCoP #MedEd #MedTwitter
Ben Ponvilawan, MD, MS retweeted
We encourage you to check out our article on tips for finding a HemeOnc job in the U.S. while on a J1 visa. It offers practical advice from individuals who have navigated the same process! @ASCO #ASCOConnections @RohitBanwar
Ben Ponvilawan, MD, MS retweeted
🎤 Excited to present at the #NCCN2025 Conference! @NCCN
📊 Racial Disparities in NSCLC Survival Outcomes: A Systematic Review & Meta-Analysis
✅ Asian/API patients had significantly better OS vs. White patients
❌ No significant differences in OS for Black or Hispanic patients
🔍 Our findings highlight genomic drivers & evolving treatment access. Let’s advance equity in lung cancer care.
@OncoAlert @NCCNnews
🧠 #Oncology #LungCancer #NSCLC #HealthEquity #CancerDisparities #CancerResearch #MedTwitter
Ben Ponvilawan, MD, MS retweeted
Our paper recently published in @JAMANetworkOpen Doublet IO might be more beneficial in patients with pd-l1 negative squamous cell lung cancer
jamanetwork.com/journals/jam…
Ben Ponvilawan, MD, MS retweeted
Excited to celebrate the outstanding fellowship match results of our UMKC Internal Medicine residents! We’re proud of your achievements and look forward to your continued success in the next chapter of your careers. #UMKCIM #FellowshipMatch2024
Deeply honored to become a Heme/Onc fellow at @NorthwesternMed starting next July!
Super grateful to my family, friends, mentors, @umkcIM, and everyone who has supported me throughout the long journey.
@NUHemOncFellow @hemeoncfellow #Match2025 #HemeOnc
Our correspondence is now available on @TheLancet!
Differences in HCC etiology may contribute to the positive result of camrelizumab plus rivoceranib in CARES-310 trial, in contrast to other IO+TKI trials. Thank you @MarcRothMD @SLCI_KC for the support.
thelancet.com/journals/lance…
Ben Ponvilawan, MD, MS retweeted
🔥🚨1/2 Hot off the press.
Just published @JCOOP_ASCO
#Guide to Understanding & Supporting #International #MedicalGraduates in #Hematology/#Oncology by @ASCO #IMGs Community of Practice.
I’m honored to be part of this work with GREAT COLLEAGUES.
👇🏼
tinyurl.com/2su6r8zx
Ben Ponvilawan, MD, MS retweeted
This is a nice summary of the mechanisms of action of various KRAS inhibitors from Adrienne Cox & @cjder23 in their @ScienceMagazine perspective.
The @Boehringer KRAS degrader in @ScienceMagazine
science.org/doi/10.1126/scie…
Perspective from Adrienne Cox & @cjder23
science.org/doi/10.1126/scie…
Ben Ponvilawan, MD, MS retweeted
New @NCCN guidelines for Breast/Ovarian/Pancreatic Cancer Genetics posted at nccn.org/professionals/physi…
New recommendation that #PancreaticCancer screening be “considered” for all BRCA2 and ATM pathogenic variant carriers by age 50, even without known family history
Happy to present a mini oral presentation about identifying patient population that may benefit more from double ICI regimen compared to those with single ICI. Thank you for the gracious support and mentorship from @dhruvsxu @RamSubraMD
#WCLC24 @hemeoncfellow @IASLC
Ben Ponvilawan, MD, MS retweeted
Successful Hemeonc #Match2025 fellowship applicants meet up led by @drtulsijose at the #WCLC24 conference, San Diego. Future of #hemeonc is bright with PDs like @RManochakian advocating for Diversity, Equity & Inclusivity.
@vyasabhinav2
@sawyer_bawek
@SakditadMD
@BPonvilawan
Ben Ponvilawan, MD, MS retweeted
Proudly presenting my e-poster research at #WCLC24
Excited to share insights and contribute to the conversation!
EP.11A.29 C-Reactive Protein's Impact on Immune Adverse Events in Non Small Cell Lung Cancer Patients Undergoing Immunotherapy: Meta-Analysis
@IASLC @hemeoncfellow
Ben Ponvilawan, MD, MS retweeted
🥳
Congratulations! @KanishkaUttam for 2 posters here! And @BPonvilawan for mini oral presentation
Such a strong work!
We will do great in matching this year!
🩺🪬
@hemeoncfellow
@HemOncFellows
@IASLC
#WCLC24
Ben Ponvilawan, MD, MS retweeted
🔥🚨@OncoAlert HOT OFF THE PRESS.
Just presented at the presidential symposium @IASLC #WCLC24
Results of #HARMONi2 trial of
#Ivonescimab VS #Pembrolizumab in advanced non-small cell #LungCancer with PD-L1 >1%.
✅ Significant ⬆️mPFS
11.14 vs. 5.82 months (HR 0.51)
#Benefit in:
✅PD-L1 low (1-49%) & High (>50%)
✅Squamous or Non-Squamous
